Citations

Mayo Clinic

Clear

53 citation(s) found for "Seheult, Jansen".

HLA ‐antibody testing female donors with a pregnancy history augments the low titer group O whole blood supply
Jochumsen, Emilie A , Seheult, Jansen N , Sprogøe, Ulrik , Vieni, Casey , Yazer, Mark H

Transfusion | November 14, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1111/trf.70485 | PMID 43031507 Get It

Abstract Background Low titer group O whole blood (LTOWB) use across the United States is increasing. This simulation calculated the number of female donors who would qualify for LTOWB donation if HLA‐antibody screening was implemented in different strategies. Methods Using US nativity data and information on blood donors from 2023, a model was constructed that calculated how many of these donors would be males and nulliparous females, neither of which require HLA‐antibody screening before LTOWB donation. The model then calculated how many parous females would be HLA‐antibody sensitized based on each woman's parity in three antibody screening scenarios: all parous women, all parous women ≥50 years old, and all parous women older than the 99th percentile of the age of final birth. These calculations were performed for RhD‐negative and RhD‐positive donors. Results The model calculated that there would be 222,239 RhD‐negative male and 74,655 nulliparous RhD‐negative female donors. If all group O RhD‐negative parous females were screened, 109,479 were calculated to not be HLA‐sensitized for a total of 406,373 LTOWB eligible donors. If only the group O RhD‐negative females ≥50 years were screened, 59,138 donors would not be HLA‐sensitized for a total of 356,032 LTOWB eligible donors. If only the group O RhD‐negative females ≥42 years, the 99th percentile for last birth age, were screened, 80,375 donors would not be HLA‐sensitized for a total of 377,269 LTOWB eligible donors. Higher numbers of LTOWB donors were realized when RhD‐positive males and females were modeled. Conclusion HLA‐antibody screening realizes additional LTOWB donors.
Rate of Future Hemolytic Disease of the Fetus and Newborn Following the Prehospital Transfusion of RhD-Positive Blood Products to Females of Childbearing Potential in the United States of America
Yazer, Mark H. , Vieni, Casey , Seheult, Jansen N.

Prehospital Emergency Care | August 28, 2026 | Volume: No volume available | Issue: No issue available | Pages: 1-5

10.1080/10903127.2026.2725214 | PMID 42664369 Get It

A stochastic, physiology-based digital twin model of hemostasis and oxygenation in trauma resuscitation
Vieni, Casey , Iftekharuddin, Anika, Ward, Kevin, Pittman, Roland, Norgan, Andrew, Neal, Matthew, Triulzi, Darrell, Spinella, Phillip, Sperry, J L, Yazer, Mark, Ward, Kevin R. , Seheult, Jansen, Iftekharuddin, Anika, Pittman, Roland Nathan , Spinella, Philip C. , Yazer, Mark H. , Seheult, Jansen N.

No container title available | July 8, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-10273801/v1 | PMID 42466392 Get It

Abstract Hemorrhagic shock is a common emergency that accounts for more than 10% of global mortality and up to 40% of trauma-related mortality. The Advanced Trauma Life Support (ATLS) guidelines outline resuscitation strategies in patients with massive hemorrhage based on clinical trial and observational data. Early intervention with fluids and/or blood products is recommended during resuscitation as key to maintaining vascular patency, stabilizing a patient’s blood pressure, maintaining tissue oxygenation, and limiting shock. From a transfusion perspective, there is wide heterogeneity in the quality of blood products due to donor and manufacturing variation. The optimal transfusion strategy for massive hemorrhage remains unclear. In silico models of resuscitation may offer a means to evaluate the effectiveness and safety of various resuscitation protocols. Here we describe a stochastic multicompartment model of fluid balance and resuscitation that includes (i) cardiovascular hemodynamics, (ii) body fluid compartments and capillary solute exchange, (iii) the ability to alter hemorrhage, resuscitation, and hemostasis parameters, and (iv) tissue oxygenation and capillary-alveolar gas exchange. Building upon deterministic frameworks, this stochastic model more faithfully reflects the clinical heterogeneity of bleeding patients at a level I trauma center. This allows for a proof of concept in silico trial comparing crystalloids, conventional component therapy (CCT), i.e. red cell, platelet and plasma components, to cold-stored low titer group O whole blood (LTOWB). In an in silico cohort of ATLS class III (>30% and ≤40% blood volume lost) hemorrhage, LTOWB resuscitation reduced the time spent in the critical hemostatic window (platelet count <50x109/L, INR≥2, hemoglobin (Hgb) <8 g/dL and fibrinogen <150 mg/dL) compared with CCT (90.59 vs. 147.62 minutes; p=0.04), with no difference in predicted event-free survival (t = 240 minutes; cardiac < 1.5, fluid overload > 10% or SBP > 150% of the starting SBP, or Hgb < 3.0 g/dL). In a separate cohort of ATLS class IV (>40% blood volume lost) hemorrhage, LTOWB yielded a higher predicted event-free survival (74%) versus the CCT arm (69%, p < 0.01). We demonstrate how this in silico platform can function as a digital twin for hemorrhagic trauma enabling precision transfusion strategies, and in parallel, an operational twin to support blood banks to forecast blood product demand and inform massive transfusion protocols and clinical trial design.
Revisiting KIR restriction and CD94 expression in diagnostic criteria for NK–large granular lymphocytic leukemia
Otteson, Gregory E., Jevremovic, Dragan, Morice, William G. , Timm, Michael, Hsi, Eric D. , Olteanu, Horatiu , Shi, Min , Morice, William George , Timm, Michael M, Hsi, Eric D , Olteanu, Horatiu , Shi, Min , Seheult, Jansen N. , Jevremović, Dragan , Horna, Pedro

Blood Advances | May 8, 2026 | Volume: 10 | Issue: 17 | Pages: 6043-6046

10.1182/bloodadvances.2026020572 | PMID 42102292 Get It

Soluble Thrombomodulin Links Viremia and Mortality During COVID‐19: Results From the ACTIV‐4a Trial
Zuchelkowski, Benjamin E. , Inman, Kyle, Nouraie, S Mehdi, Beru, Neeharika, Naqvi, Asma , Qin, Shulin, Yeh, Calvin H., Zhang, Yingze , Shah, Faraaz , Sharma, Lokesh , Zhang, Lianghui , Morris, Alison, Kim, Paul Y., Jacobs, Jana L. , Nouraie, Mehdi , Inman, Kyle W , Nouraie, Seyed Mehdi , Shah, Faraaz A , Zhang, Lianghui , McVerry, Bryan J , Morris, Alison , Neal, Matthew D , Seheult, Jansen N , Kitsios, Georgios D , Mellors, John W , Lawrence, Daniel A , Kim, Paul Y , Jacobs, Jana L , Bain, William G , Zhang, Yingze , Inman, Kyle , Naqvi, Asma , Qin, Shulin , Yeh, Calvin H., Sharma, Lokesh , Dela Cruz, Charles S , Seheult, Jansen N.

Journal of the American Heart Association | May 6, 2026 | Volume: 15 | Issue: 10 | Pages: No page available

10.1161/jaha.125.047693 | PMID 42089155 Get It

Background COVID‐19 and other respiratory viral infections can cause cardiovascular complications. SARS‐CoV‐2 virions are found in the blood, and circulating viral RNA levels are associated with death. We hypothesized that viremia can induce thrombotic endotheliopathy that contributes to death and studied this relationship in patients hospitalized for COVID‐19 and enrolled in the ACTIV‐4a (Accelerating COVID‐19 Therapeutic Interventions and Vaccines) randomized trial of antithrombotic therapy. Methods We quantified SARS‐CoV‐2 nucleocapsid RNA and protein in plasma and measured their associations with clinical outcomes and biomarkers of thromboinflammation and endotheliopathy. We used Cox regression and Fine–Gray competing risk models to analyze survival and thrombosis. We conducted causal mediation analysis to explore whether thrombotic endotheliopathy mediates the relationship between viral RNA and death. Results In 93 patients, SARS‐CoV‐2 RNA and N‐antigen were higher in nonsurvivors. Baseline viral RNA levels were associated with increased 90‐day death (hazard ratio [HR], 1.31 [95% CI, 1.17–1.46]) and thrombosis (HR, 1.35 [95% CI, 1.24–1.47]). Viral RNA more effectively predicted survivorship than N‐antigen levels. Soluble thrombomodulin, a biomarker of thrombotic endotheliopathy, positively correlated with viral RNA levels. Mediation analysis revealed that soluble thrombomodulin accounts for 12.2% (95% CI, 0.1%–32.3%; P =0.048) after adjustment for age and sex of the relationship between viral RNA and the 90‐day mortality rate. Conclusions Elevated plasma SARS‐CoV‐2 RNA levels are associated with death in ACTIV‐4a, which is causally mediated in part by soluble thrombomodulin. We propose that lung–blood viral dissemination is a potential mechanism for cardiovascular complications of respiratory viruses. Registration URL: https://www.clinicaltrials.gov ; Unique Identifier: NCT04505774.
Low titer group O whole blood inventory conservation: The effect of implementing group A whole blood at a simulated civilian trauma center
Jochumsen, Emil Ainsworth , Gurney, Jennifer, Jenkins, Donald, Seheult, Jansen N. , Spinella, Philip C. , Yazer, Mark H. , Jochumsen, Emilie A , Yazer, Mark H , Spinella, Philip C , Seheult, Jansen N , Gurney, Jennifer M. , Jenkins, Donald, Sprogøe, Ulrik

Transfusion | April 18, 2026 | Volume: 66 | Issue: 7 | Pages: 1289-1298

10.1111/trf.70235 | PMID 41999095 Get It

Abstract Background Substituting group A whole blood (GAWB) might relieve some of the burden on the low titer group O whole blood (LTOWB) inventory. This simulation examined the effect of implementing GAWB at a large trauma hospital. Study Design and Methods A civilian trauma center with LTOWB and GAWB par levels set to 22 and 10 units, respectively, was modeled as the baseline. The average daily number of WB recipients was 0.5 who received an average of four WB units per patient. LTOWB was issued in packages of five and all had to be consumed before a group A patient could be switched to GAWB. Several variations on the baseline simulation were also modeled. Results In the baseline simulation, there was a median (interquartile range, IQR) of 1 (0–2) GAWB and 16 (13–19) LTOWB recipients per month. The median (IQR) GAWB and LTOWB units transfused per month was 2 (0–9) and 56 (42–72), respectively. Fourteen percent of group A patients received any quantity of GAWB. The variations that had the most impact on GAWB usage included increasing the number of WB recipients to 2.5 per day where the median (IQR) monthly number of GAWB recipients and units transfused increased to 4 (3–5) recipients and 21 (12–29) units, respectively, and when the average WB requirements increased to eight units per patient resulting in transfusing a median (IQR) of 10 (5–15) GAWB units per month to 3 (1–4) recipients. Discussion Under routine civilian hospital circumstances, implementing GAWB will have a modest impact on LTOWB inventory.
A Retrieval-Based Approach for Automatic Interpretation of Multi-Analyte Laboratory Profiles
Khandelwal, Sarthak, Leger, Rachel, Navitskas, Serena, Pruthi, Rajiv, Chen, Dong , Tavolara, Thomas E, Chen, Dong , Tavolara, Thomas Erol , Leger, Rachel, Navitskas, Serena D., Pruthi, Rajiv K. , Seheult, Jansen N.

The Journal of Applied Laboratory Medicine | April 17, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1093/jalm/jfag063 | PMID 42189159 Get It

Abstract Background Interpretation of multi-analyte laboratory profiles, such as lupus anticoagulant (LAC) testing, requires integration of numerous test results and clinical information. However, this process is time-consuming, requires domain knowledge, and has limited scalability. Given that rule-based systems are rigid and difficult to maintain and large language models pose risks of “hallucinations,” we developed and evaluated a novel retrieval-based approach to automate LAC profile interpretation to improve efficiency while maintaining fidelity and reliability for clinical use. Methods Our method processes laboratory values through ensemble random forest (RF) models to retrieve the most similar expert interpretation from a curated database of 347 previously interpreted LAC profiles. The system's performance was assessed through technical accuracy metrics, a work flow efficiency timing study, and expert review of interpretation accuracy for held-out cases. Results Technical validation demonstrated high accuracy in retrieving correct interpretative elements (median: 93% accuracy, interquartile range [IQR]: 67% to 100%). Retrieval accuracy was highly correlated with the prevalence of a given element (ρ = 0.8307). In a timing study of 93 consecutive LAC profiles, ensemble-assisted interpretation achieved a median time of 22 s per report (IQR: 16 s to 31 s), representing a 78.6% total reduction compared to manual interpretation (median: 118 s, IQR: 96 s to 172 s; t = 18.61, P &lt; 0.001). Furthermore, 92.5% of AI-assisted interpretations were completed within 60 s, exceeding the target of 85%. Expert review confirmed 100% concordance for LAC presence/absence. Conclusions The proposed approach significantly improves efficiency of complex laboratory interpretation for LAC profiles, while maintaining consistency and high fidelity. Future studies will explore the method’s inherent extensibility to the interpretation of other multi-analyte laboratory profiles.
Ethical dilemmas in the use of artificial intelligence in transfusion medicine
Seheult, Jansen N. , Malone, Jay R. , Yazer, Mark, Malik, Momin , Yazer, Mark H , Seheult, Jansen N , Jackson, Brian R. , Malik, Momin M. , Yazer, Mark H.

Vox Sanguinis | February 18, 2026 | Volume: 121 | Issue: 4 | Pages: 417-429

10.1111/vox.70183 | PMID 41702690 Get It

Abstract Artificial intelligence (AI) and machine learning (ML) are beginning to enhance key workflows across blood banking (BB) and transfusion medicine (TM), including donor engagement, inventory forecasting, immunohaematology interpretation, haemovigilance and clinical decision support. These tools can extract signals from large, diverse datasets to improve efficiency, consistency and timeliness of care while enabling more proactive patient blood management. At the same time, TM is uniquely sensitive to safety and trust, so the field must pair innovation with disciplined validation and governance. This review surveys emerging applications and distils a balanced ethics and oversight framework tailored to TM and BB practice. Core elements include outcome‐focused validation and continuous monitoring; targeted fairness testing where biological or scientific plausibility suggests subgroup differences; layered transparency that distinguishes transparency, interpretability and explainability; and privacy by design with proportionate consent. We emphasize human oversight at every step: clinicians and laboratorians evaluate, monitor and troubleshoot models, perform tasks AI cannot, integrate multiple inputs to make decisions and interact with AI through guardrails such as intended‐use statements, confidence thresholds and clear override pathways. Accountability is shared across users, service directors, institutions and regulators. When implemented with these safeguards, AI can reduce preventable errors, improve resource allocation and support more equitable access to safe transfusion. The goal is principled pragmatism that protects patients and donors while enabling timely adoption of well‐validated tools.
Performance of molecular classifiers relative to the international prognostic index (IPI) for overall and event-free survival in diffuse large B-cell lymphoma (DLBCL)
Cholack, George , King, Rebecca L. , Mwangi, Raphael , Nowakowski, Grzegorz S. , Ansell, Stephen M. , Novak, Anne J. , Cholack, George A , Edelmann, Dominic , Walker, Janek S. , Novak, Joseph P. , Wang, Yucai , Mou, Eric , Syrbu, Sergei , Seheult, Jansen N. , Vodička, Prokop , Paludo, Jonas , Witzig, Thomas E. , Hsi, Eric D. , Link, Brian K. , Habermann, Thomas M. , Maurer, Matthew J. , Cerhan, James R.

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 5301-5301

10.1182/blood-2025-5301 Get It

Abstract Over the past decade, classification systems using high-throughput genetic data have been developed to identify molecular subtypes of DLBCL. Although not a primary goal, these classifiers were also proposed as prognostic factors in their respective publications. To date, however, no study has directly compared these classifiers' ability to predict overall (OS) and event-free survival (EFS) in the same cohort. Herein, we sought to systematically compare predictive performance, benchmarked against the IPI, of several current established molecular classifiers and evaluate if any add significant independent prognostic information beyond the IPI. WES (including paired germline filter) and RNAseq data from newly diagnosed DLBCL patients (N=432; 2018 WHO criteria) in the Mayo Clinic/University of Iowa Lymphoma Molecular Epidemiology Resource (MER) were available for analysis (WES n=112, RNAseq n=40, or both n=280). The number of cases able to be classified (including as unclassified) for each classifier was as follows: IPI (432, 100%), cell-of-origin (COO, by Hans algorithm; 346, 80.1%), refined COO (by gene expression with Dark Zone Signature; 320, 100%), Haematological Malignancy Research Network (HMRN; 349, 89.0%), B-cell state (320, 100%), Lymphoma Ecotype (320, 100%), Lymphoma Microenvironment (LME; 320, 100%), Tumor microenvironment (TME26; 320, 100%), SubLymE (312, 97.5%), LymphGen (358, 91.3%), and DLBclass (223, 58.2%). OS was defined as time from diagnosis to all-cause death while EFS was defined as time from diagnosis to disease progression, initiation of second-line treatment, or all-cause death. We calculated Harrell's c-statistics for each Cox proportional hazards model evaluating the discriminative performance of each classifier in predicting OS/EFS. Using bootstrap validation, we obtained optimism-corrected c-statistics, which we report in the results. We performed likelihood ratio tests (LRT) comparing a univariable Cox model with IPI alone and models including both IPI and a given classifier to assess if a classifier provided independent prognostic information beyond the IPI. All patients were treated with immunochemotherapy (IC) with curative intent, 247 (57%) were male, median age at diagnosis was 65 years (IQR 55-72 years), 390 (96%) were White, 209 (60%) had GCB subtype by Hans, 22 (5.1%) had MYC double-hit by FISH (MYC and BCL2 or BCL6), and 162 (37.9%) had an IPI ≥ 3. The median follow-up was 7.0 years, 167 (39%) experienced an event, and 137 (32%) died. In a univariable Cox model, the c-statistic for IPI predicting OS was 0.66 (95% confidence interval [CI] 0.61-0.70). All other classifiers had c-statistics of ≤0.56. The c-statistic for IPI predicting EFS was 0.64 (95% CI 0.60-0.69), and all other classifiers had c-statistics of ≤0.58. The univariate DLBclass results for OS and EFS were not significantly impacted when restricted to cases with confidence &gt;0.7 (n=136). In Cox models of IPI alone versus IPI plus an individual classifier, the only classifier that provided statistically significant, independent information for OS was TME26 (LRT p=0.02). Adjusting for IPI, patients who were TME26-negative had significantly inferior OS compared to TME26-positive cases (HR 1.63, 95% CI 1.07-2.47; p=0.02). For EFS, DLBclass (restricted to confidence &gt;0.7) added significant prognostic information beyond IPI (LRT p=0.02). This finding was largely driven by C5 subtype; relative to C1 subtype and adjusting for IPI, C5 subtype had significantly inferior EFS (HR 5.53, 95% CI 1.81-17.0; p=0.003). In summary, we compared prognostic performance of multiple DLBCL molecular classifiers with respect to OS and EFS in a single real-world, prospective cohort of newly diagnosed, IC-treated DLBCL. Our data supports two key findings: all classifiers had modest performance for prognosis, and none individually outperformed the IPI in predicting OS nor EFS. Second, only TME26 and DLBclass (confidence &gt;0.7) provided additional prognostic information beyond that captured by the IPI for OS and EFS, respectively. This finding suggests that the tumor immune microenvironment and characteristics of C5 DLBCLs (ABC-subtype, CD79B mutations) can potentially offer significant independent information for predicting survival and response to front-line immunochemotherapy. If replicated, these findings could inform risk-adapted treatment approaches and aid in identifying high-risk patients for enrollment in genomically-informed clinical trials.
Genetic evolution of Waldenström macroglobulinemia across disease stages
Zanwar, Saurabh , Dasari, Surendra , Kumar, Shaji , Seheult, Jansen N. , Busso, Miles Del, Miller, Ross H. , Nowakowski, Kevin E., Novak, Anne J. , King, Rebecca L. , Kourelis, Taxiarchis , Kyle, Robert A. , Ansell, Stephen M. , Kapoor, Prashant , Abeykoon, Jithma P. , Seheult, Jansen N , Novak, Joseph P. , Paludo, Jonas , Bhardwaj, Vaishali , Miller, Ross, Yi, Dongni , Habermann, Thomas M. , Asada, Shuhei , Mondello, Patrizia , Jevremović, Dragan , Go, Ronald S. , Gonsalves, Wilson I. , Leung, Nelson , Dispenzieri, Angela , Lin, Yi , Rajkumar, S. Vincent , Gertz, Morie A. , Witzig, Thomas E.

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 3540-3540

10.1182/blood-2025-3540 Get It

Abstract Background: Waldenström Macroglobulinemia (WM) is an indolent B-cell lymphoplasmacytic lymphoma characterized by heterogeneous clinical behavior and variable progression patterns. While MYD88L265Pand CXCR4 mutations are frequently encountered, the broader genomic landscape underpinning disease evolution from smoldering WM (SWM) to active treatment naïve WM (TNWM), post-treatment remission WM (PTWM) and relapsed/refractory WM (RRWM) remains incompletely understood. To address this gap, we studied the mutational profile across the WM disease spectrum. Methods We performed whole exome sequencing (WES) on sorted (CD19 and/or CD138) bone marrow aspirates of patients across the spectrum of WM. Paired germline sequencing was performed using peripheral blood mononuclear cells (PBMCs). Unique molecular identifier-tagged reads were deduplicated using fgbio. WES data were processed through the Sarek pipeline. Any valid mutation from either caller, present on the index or in COSMIC was considered. Copy number variations (CNVs) were inferred via CNVkit and summarized at the gene and arm level (≥50% directional change). Mean tumor and germline coverages were 174X and 74X, respectively. Fisher's exact test was used for enrichment and hypergeometric test for overlap analyses. Results A total of 78 high-quality WM samples [15 SWM, 44 TNWM, 13 RRWM, 6 PTWM in remission (all with paired TNWM samples)] were sequenced. The mutational burden varied across disease states (median SWM=1.48 m/Mb, TNWM= 1.12 m/Mb, RRWM = 1.59 m/Mb; p=0.04). Density plots revealed bimodal VAF distributions, consistent with clonal and subclonal architectures in WM. Overall, 77% harbored a MYD88L265P mutation by WES. Among MYD88^WT^ patients, AS-PCR identified MYD88L265P in 4 (25%) not detected by WES, raising the overall mutation rate to 83%, plus one with a non-L265P variant. Low VAF (&lt;10%) MYD88L265P mutations were seen in 6% of matched PBMCs. MYD88 copy number gain was seen in 2 (17%) MYD88WT TNWM patients. CXCR4 mutations were detected in 38% by WES (18% each frameshift and nonsense). Two (4%) CXCR4WT samples were positive by PCR, giving an overall rate of 40%. CXCR4 mutations were more frequent in RRWM (54%) vs TNWM (41%) and SWM (27%), though not statistically significant. Del(6q) and Del(17p) were noted in 16% (n=12) and 7% (n=5) of patient samples. All del(17p) events were noted in TNWM samples and in one paired post-treatment sample. Overall rate of del(17p) and TP53 mutation was 14% (n=11). RRWM was enriched in ARID1A alterations, a gene implicated in chromatin remodeling and plasma cell identity formation [38% (n=5) in RRWM vs. 11% (n=6) in TNWM and SWM], compared to TNWM and SWM p=0.03]. Alterations in NF-kB signaling gene MAP3K14 were more frequent in RRWM (31%, n=4) compared to the SWM/TNWM cohort [(7%), n=4; p=0.036). We noted an enrichment in the TP53 mutation rate in RRMW [n=3, 23%, OR 7.7] compared to TNWM and SWM cohorts [n=2, 4%), p=0.04]. Mutations in FUBP1 (p=0.03), an upstream regulator of MYC, and CARD11 (p=.043), a B-cell signaling scaffold protein were also more frequent in RRWM. Notably, none of the SWM patients harbored an ARID1A alteration (p=0.057), suggesting acquisition during progression. CNV analysis revealed that MAP3K14 amplifications were frequent in RRWM (n=3, 23%) compared to SWM/TNWM [n=2 (4%), p=0.043]. RRWM samples showed increased CD79B mutations (15%) and significant overlap with the C5/ABC diffuse large B-cell lymphoma (DLBCL) genomic cluster (Chapuy et al., Nat. Med. 2018; p=0.007). This overlap remained significant after excluding MYD88L265P (p=0.019), driven by CARD11, CD79B, and IGLL5, suggesting that a subset of RRWM may acquire an ABC DLBCL-like mutational profile. These findings warrant further investigation using transcriptional profiling. Conclusions This study provides a genomic map of WM evolution from precursor to relapse. Increasing somatic mutations and CNVs support stepwise progression. Enrichment of genes involved in chromatin remodeling and plasma cell identity formation (ARID1A), NF-kB or BCR signaling (CARD11, MAP3K14), and DNA damage repair (TP53) were noted at relapse, all of which have been shown to drive aggressive disease biology. Emergence of an ABC-like genotype in a proportion of RRWM indicates convergent evolution with aggressive lymphomas. Transcriptional studies are warranted to explore this further.